102 related articles for article (PubMed ID: 25700423)
1. A 2-way miRror of red blood cells and leukemia.
Grimes HL; Meyer SE
Blood; 2015 Feb; 125(8):1202-3. PubMed ID: 25700423
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors.
Wang LS; Li L; Li L; Chu S; Shiang KD; Li M; Sun HY; Xu J; Xiao FJ; Sun G; Rossi JJ; Ho Y; Bhatia R
Blood; 2015 Feb; 125(8):1302-13. PubMed ID: 25515961
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-486-5p is an erythroid oncomiR of the myeloid leukemias of Down syndrome.
Shaham L; Vendramini E; Ge Y; Goren Y; Birger Y; Tijssen MR; McNulty M; Geron I; Schwartzman O; Goldberg L; Chou ST; Pitman H; Weiss MJ; Michaeli S; Sredni B; Göttgens B; Crispino JD; Taub JW; Izraeli S
Blood; 2015 Feb; 125(8):1292-301. PubMed ID: 25533034
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
7. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
8. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Wen F; Cao YX; Luo ZY; Liao P; Lu ZW
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):1-8. PubMed ID: 30366670
[TBL] [Abstract][Full Text] [Related]
10. [Ph1-positive leukemia: cytogenetic outline and prognosis].
Misawa S
Nihon Rinsho; 1992 Jun; 50(6):1274-80. PubMed ID: 1518145
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis.
Choi J; Kim YK; Park K; Nah J; Yoon SS; Kim DW; Kim VN; Seong RH
Blood; 2016 Oct; 128(17):2117-2129. PubMed ID: 27605510
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
Lopotová T; Záčková M; Klamová H; Moravcová J
Leuk Res; 2011 Jul; 35(7):974-7. PubMed ID: 21511335
[TBL] [Abstract][Full Text] [Related]
13. The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review).
Di Stefano C; Mirone G; Perna S; Marfe G
Oncol Rep; 2016 Feb; 35(2):614-24. PubMed ID: 26718125
[TBL] [Abstract][Full Text] [Related]
14. miRNAs in chronic myeloid leukemia: small molecules, essential function.
Litwińska Z; Machaliński B
Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267
[TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365.
Min QH; Wang XZ; Zhang J; Chen QG; Li SQ; Liu XQ; Li J; Liu J; Yang WM; Jiang YH; Xu YM; Lin J; Gao QF; Sun F; Zhang L; Huang B
Exp Cell Res; 2018 Jan; 362(2):386-393. PubMed ID: 29223442
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
17. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Zhao L; Shan Y; Liu B; Li Y; Jia L
Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
[TBL] [Abstract][Full Text] [Related]
18. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Farhadi E; Zaker F; Safa M; Rezvani MR
Tumour Biol; 2016 Oct; 37(10):14117-14128. PubMed ID: 27517565
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Wu J; Wang A; Li X; Chen C; Qi Z; Hu C; Wang W; Wu H; Huang T; Zhao M; Wang W; Hu Z; Liu Q; Wang B; Wang L; Li L; Ge J; Ren T; Xia R; Liu J; Liu Q
Cancer Biol Ther; 2019; 20(6):877-885. PubMed ID: 30894066
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
